Close Menu

NEW YORK – Skin cancer diagnostics company Castle Biosciences reported after the close of the market on Thursday preliminary performance results for the fourth quarter 2019 that showed a 37 percent year-over-year increase in volume for the company's DecisionDx-Melanoma test.

For the three months ended Dec. 31, 2019, the company delivered 4,480 DecisionDx-Melanoma test reports, compared to 3,270 reports during Q4 2018. Castle also delivered 434 DecisionDx-UM test reports for uveal melanoma in Q4, up 13 percent from 385 reports in Q4 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.